Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Conlin K. et al, (2024), Vaccine, 45
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
Qadri F. et al, (2024), Lancet, 404, 1419 - 1429
Modelling Salmonella Typhi in high-density urban Blantyre neighbourhood, Malawi, using point pattern methods.
Khaki JJ. et al, (2024), Sci Rep, 14
Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
Bijukchhe SM. et al, (2024), Vaccine
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.
Hill M. et al, (2023), BMJ Open, 13
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Kelly E. et al, (2023), J Infect, 87, 230 - 241
Direct inference and control of genetic population structure from RNA sequencing data.
Fachrul M. et al, (2023), Commun Biol, 6
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Liu X. et al, (2023), J Infect, 87, 18 - 26
Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
Khanam F. et al, (2023), Vaccine, 41, 3137 - 3140
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Liu X. et al, (2023), The Journal of infection, 86, 540 - 541
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
EWER K., (2023), Clinical and Experimental Immunology
Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials.
Bendor-Samuel OM. et al, (2023), Arch Dis Child, 108, 26 - 30
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060